Company contact: Maria Maccecchini, CEO
QR Pharma, Inc.
484 253 2296
Maccecchini@qrpharma.com

QR Pharma to Present at 2nd Annual World Congress of NeuroTalk

Berwyn, PA, May 18, 2011 QR Pharma, Inc. a developer of novel compounds to treat Alzheimer's disease and neurodegenerative disorders, announced today that Dr. Maria Maccecchini, chief executive officer, will speak at the BIT 2nd Annual World Congress of NeuroTalk-2011 in Dalian, China. Dr. Maccecchini will co-chair a session on Anti-Neurodegenerative Drug Discovery and will also present Posiphen® Treatment of Alzheimer Patients Resulting in Normalized Levels of Amyloid Precursor Protein, Tau, Complement and Other Neurotrophic Factors. The session will be held on Wednesday May 25, 2011, at 1:30 PM at the Dalian World EXPO Center, China.

About Posiphen®, QR's Lead Compound
Posiphen® is in clinical development as an oral treatment for Alzheimer's disease. It is a small orally active compound with high blood brain barrier permeability, which lowers amyloid precursor protein (APP) levels. Posiphen reduces the rate of synthesis of APP in cell cultures, normal, transgenic and trisomic mice. APP is cleaved into a number of toxic peptides, including Aβ42, which is cleaved from the middle while the others are cleaved from the N- and C- terminal ends. These peptides attack multiple pathways of neuronal cell life leading to synaptic loss and nerve cell death. This degeneration of the brain induces dysfunction, neuroinflammation and leads to cognitive impairment and neurodegeneration.

QR conducted a trial in patients with mild cognitive impairment to confirm Posiphen's mechanism of action in humans and correlate it with the pharmacokinetics of the compound and its metabolites in CSF and plasma. Posiphen lowers levels of APP and tau by about 40%, approaching the levels found in healthy volunteers.

About QR Pharma, Inc.
Headquartered in Radnor, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment, Alzheimer's disease, Parkinson's disease and Down syndrome. QR currently has two product development programs - Posiphen for early stage AD and BNC for advanced AD. For more information on QR Pharma, please visit the company's website, www.qrpharma.com.

Contact: Maria Maccecchini, CEO
Tel: 610 209 8454
Maccecchini@qrpharma.com
www.qrpharma.com